Xenon Pharmaceuticals

Xenon Pharmaceuticals will present six Azetukalner presentations at the 16th European Epilepsy Congress (5–9 September 2026, Athens), including an oral presentation of the phase‑3 X-TOLE2 study in focal onset seizures. The data include results from the randomized, double‑blind, placebo‑controlled X-TOLE2 (380 participants; Azetukalner 25 mg or 15 mg vs. placebo) and findings from patients with at least 48 months of participation in the open‑label extension. In addition, mechanistic posters will show data on possible additive effects in combination with common antiseizure medications and in‑vivo evidence; Azetukalner is a potassium channel opener in development for epilepsy, major depressive disorder and bipolar depression. » More on de.investing.com

Xenon Pharmaceuticals’ share rose to a record high of $63.96, marking a yearly increase of 102.36% and a YTD gain of 35%, with market capitalization around $6.2 billion. Analysts still see strong buy consensus and maintain a high price target of $100; the stock trades near its fair value. Q1 2026 results painted a mixed picture: EPS of -$1.17 slightly beat estimates, while no revenue was reported, missing expectations. » More on de.investing.com

Xenon Pharmaceuticals will present five abstracts at the American Academy of Neurology annual meeting, including results from the phase‑3 X‑TOLE2 study of azetukalner in focal seizures in a late‑breaking oral session and a poster session. The company will also present 48‑month interim analyses from the open‑label extension study X‑TOLE and real‑world data on titration burden and quality of life. In addition, Xenon will show preclinical data on its NaV1.1 program; azetukalner is described as a potassium channel opener being evaluated in phase‑3 studies for epilepsy and depressive disorders. » More on de.investing.com